Non-small Cell Lung Cancer
Conditions
Brief summary
This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
Detailed description
inclusion criteria Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer EGFR G719X, exon 20 insert mutation without any anti-cancer treatment history
Interventions
DRUGThird-generation EGFR-TKI
Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc.
DRUGEGFR-TKI
All EGFR-TKI
Sponsors
Hunan Province Tumor Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology * Uncommon EGFR Mutant Advanced NSCLC
Exclusion criteria
* Patients with contraindication of chemotherapy * Pregnant or breast feeding women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS | 5 years | Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OS | 5 years | Defined as the time from the start of treatment to the death of the subject due to any cause. |
| ORR | 5 years | Defined as the proportion of subjects achieving a complete remission (CR) or partial remission (PR) among all subjects. |
Countries
China
Contacts
Primary ContactYongchang Zhang, MD
Backup ContactNong Yang, MD
Outcome results
None listed